Combined analysis of whole-exon sequencing and lncRNA sequencing in type 2 diabetes mellitus patients with obesity.
Tian AnJing ZhangYu-Fei LiuYan-Xiang WuJuan LianTing-Ye WangYuan-Yuan HuJia-Jian ZhuJiangpinghao HuangDan-Dan ZhaoFang-Fang MoSi-Huan GaoGuang-Jian JiangPublished in: Journal of cellular and molecular medicine (2020)
This study sought to find more exon mutation sites and lncRNA candidates associated with type 2 diabetes mellitus (T2DM) patients with obesity (O-T2DM). We used O-T2DM patients and healthy individuals to detect mutations in their peripheral blood by whole-exon sequencing. And changes in lncRNA expression caused by mutation sites were studied at the RNA level. Then, we performed GO analysis and KEGG pathway analysis. We found a total of 277 377 mutation sites between O-T2DM and healthy individuals. Then, we performed a DNA-RNA joint analysis. Based on the screening of harmful sites, 30 mutant genes shared in O-T2DM patients were screened. At the RNA level, mutations of 106 differentially expressed genes were displayed. Finally, a consensus mutation site and differential expression consensus gene screening were performed. In the current study, the results revealed significant differences in exon sites in peripheral blood between O-T2DM and healthy individuals, which may play an important role in the pathogenesis of O-T2DM by affecting the expression of the corresponding lncRNA. This study provides clues to the molecular mechanisms of metabolic disorders in O-T2DM patients at the DNA and RNA levels, as well as biomarkers of the risk of these disorders.
Keyphrases
- peripheral blood
- end stage renal disease
- poor prognosis
- single cell
- metabolic syndrome
- type diabetes
- ejection fraction
- long non coding rna
- glycemic control
- genome wide
- chronic kidney disease
- long noncoding rna
- gene expression
- high fat diet induced
- adipose tissue
- transcription factor
- patient reported outcomes
- cell free
- skeletal muscle
- patient reported
- circulating tumor